WO2000024427A1 - Remedes contre les rhumatismes contenant un gene fadd en qualite d'ingredient actif - Google Patents
Remedes contre les rhumatismes contenant un gene fadd en qualite d'ingredient actif Download PDFInfo
- Publication number
- WO2000024427A1 WO2000024427A1 PCT/JP1999/005988 JP9905988W WO0024427A1 WO 2000024427 A1 WO2000024427 A1 WO 2000024427A1 JP 9905988 W JP9905988 W JP 9905988W WO 0024427 A1 WO0024427 A1 WO 0024427A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fadd
- rheumatism
- fadd gene
- gene
- cells
- Prior art date
Links
- 101150071111 FADD gene Proteins 0.000 title claims abstract description 40
- 239000004480 active ingredient Substances 0.000 title claims abstract description 8
- 230000006907 apoptotic process Effects 0.000 claims abstract description 19
- 241000701161 unidentified adenovirus Species 0.000 claims abstract description 9
- 208000025747 Rheumatic disease Diseases 0.000 claims description 27
- 230000000552 rheumatic effect Effects 0.000 claims description 26
- 210000005222 synovial tissue Anatomy 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 210000002437 synoviocyte Anatomy 0.000 abstract description 30
- 238000003782 apoptosis assay Methods 0.000 abstract description 4
- 230000005522 programmed cell death Effects 0.000 abstract description 4
- 230000001939 inductive effect Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 21
- 102100026693 FAS-associated death domain protein Human genes 0.000 description 17
- 108010077716 Fas-Associated Death Domain Protein Proteins 0.000 description 17
- 206010003246 arthritis Diseases 0.000 description 17
- 230000000694 effects Effects 0.000 description 13
- 238000012546 transfer Methods 0.000 description 10
- 206010015150 Erythema Diseases 0.000 description 6
- 231100000321 erythema Toxicity 0.000 description 6
- 208000009386 Experimental Arthritis Diseases 0.000 description 5
- 206010070834 Sensitisation Diseases 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 230000008313 sensitization Effects 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 102000000503 Collagen Type II Human genes 0.000 description 4
- 108010041390 Collagen Type II Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010051728 Bone erosion Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101150063416 add gene Proteins 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000030833 cell death Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 108010052621 fas Receptor Proteins 0.000 description 2
- 102000018823 fas Receptor Human genes 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101150097493 D gene Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- the present invention relates to a therapeutic agent for rheumatism containing a FAD (Fas associated death domain protein) gene as an active ingredient.
- FAD Fes associated death domain protein
- Rheumatism is a group of diseases based on the proliferation of synovial cells with various immunological abnormalities caused by internal and external factors. It is thought to be an abnormal proliferation of synovial cells accompanied by bone erosion (bone erosion and the appearance of bone erosion). Rheumatoid arthritis is characterized by regression of proliferating synovial cells, followed by replacement with fibrous tissue (Fassbender HG: Pathology of Rheumatic Diseases. Berlin, Heidelberg, Springer- Verlag, 1975), however, the mechanism of regression and rebirthment remains largely unknown. However, tissue destruction mainly in the affected joints in chronic rheumatoid arthritis may be due to abnormal production or excessive release of cytokines from synovial cells and inflammatory synovial infiltrating cells. .
- synovial tissue cells (synovial cells and inflammatory synovial infiltrating cells) play an important role in rheumatoid arthritis.
- synovial villi are proliferated and the synovial tissue cells are multi-layered.
- Synovial tissue cells are abnormally proliferating (by Daniel J. McCarty, Arthritis and allied conditions, A textbook of rheumatology 11th edition). If the abnormal proliferation of these synovial tissue cells could be suppressed, it would be useful for rheumatism treatment.
- anti-inflammatory drugs such as steroids, gold drugs, and immunomodulators are used for drug treatment of rheumatism, but drugs that specifically suppress abnormal growth of synovial tissue cells are still in practical use. It has not been converted.
- apoptosis a physiological cell death that occurs due to normal cell turnover (Br. J. Cancer, 26, 239 (1972)).
- This apoptosis is a form of programmed cell death.
- Cell necrosis involves processes that involve high fever, attack by antibodies and complement, or release of cell membrane contents by chemical factors, etc.Programmed cell death is programmed to die in vivo in advance.
- Cell death in certain groups of cells accompanied by phenomena such as cell surface curvature, nuclear chromatin condensation, and chromosomal DNA fragmentation.
- Fas-L Fas-L
- Fas-L Fas-L
- the FADD molecule was one of the molecules that played an important role in signaling of apoptosis via the Fas / Fas-L system in 1995.
- the cells are cloned (J. Biol. Chem., 270, 7795 (1995)), and that apoptosis is induced by high expression of itself (Cell, 81, 505 (1995)).
- the nucleotide sequence of the FADD gene is also disclosed in International Patent Publication WO96Z3163. Research has also been conducted on the application of the FADD gene to medical treatment, and it has been reported that the FADD gene transfer may be useful for treating brain tumors (Human Gene Therapy, 9_, 1599 (1998)). However, the application of the FADD gene to rheumatic therapy based on its action on synovial tissue has not yet been reported. Disclosure of the invention
- the present inventors have focused on the fact that rheumatic symptoms are not improved despite apoptosis due to the Fas / Fas-L system in the synovial tissue of rheumatic patients.
- FADD was found to be useful for the treatment of rheumatism.
- the present invention relates to a therapeutic agent for rheumatism containing the FADD gene as an active ingredient.
- the above-mentioned FADD gene preferably induces apoptosis, a form of programmed cell death, in synovial cells of rheumatic patients.
- the F ADD gene may be integrated into a vector, especially an adenovirus vector.
- Figure 1 shows the mortality of cells 48 hours after infection of cultured dendritic synovial cells with Aden0-FADD or Adeno-LacZ, and untreated control. This is a graph showing the mortality rate in such cases.
- Figure 2 shows the expression levels of FADD molecules 12 and 24 hours after infection of cultured synovial cells from rheumatic patients with Aden0-FADD or Adno-LacZ. It shows the results of the above.
- FIG. 3 is a graph showing the day-to-day change of arthritis score in type I collagen-induced arthritis.
- ⁇ indicates the results of the A deno-FADD introduction group (mean of 5 to 7 cases)
- ⁇ indicates the results of the A deno-Lac Z introduction group (mean of 5 to 7 cases)
- ⁇ indicates the result of the group.
- the results for the control group are shown.
- the present inventors introduced the FADD gene into synovial cells separated and cultured from the synovial tissue of a rheumatic patient using an adenovirus vector, and examined the effects thereof.
- adenovirus vector As explained in the pharmacological test section below, most cultured synovial cells were killed by FADD gene transfer. This indicates that in vitro it was confirmed that apoptosis was induced in synovial tissue cells due to high expression of FADD molecules, and the usefulness of FADD gene transfer as rheumatic therapy. Suggests.
- the effect of the FADD gene transfer using an adenovirus vector in a collagen-induced arthritis model which is widely used as an animal model for examining the effects on rheumatism, was also examined.
- the FADD gene As a method of introducing the FADD gene, it has been reported that the FADD gene is transferred (or introduced) to glioma cells by incorporating the FADD gene into an adenovirus vector (Human Gene Therapy, 9_, 1983 (1998)). Therefore, the effect of introducing the FADD gene into synovial cells of rheumatic patients was examined according to the method described in this document.
- the ratio of the titer of A deno-FADD to the cultured synovial cells (hereinafter abbreviated as MOI) is 5, 10, 50, 100, and 200.
- Figure 1 shows the mortality rate of cultured synovial cells from rheumatic patients.
- a deno-Lac Z an adenovirus vector incorporating the yS-galactosidase gene
- Adeno-FADD killed cultured synovial cells from rheumatic patients in a viral titer-dependent manner, while Adeno-LacZ had no effect.
- FADD molecule The expression of FADD molecule in synovial cells after Adeno-FADD infection was examined.
- a deno- the F AD D or A deno- L ac Z are infected with MO I 1 0 0, 1 2 and 2 4 hours after the cytoplasm The protein was extracted and subjected to immunoprototyping using an anti-FADD antibody.
- FIG. 2 shows the results of an immunoblot showing the expression of FADD molecules in synovial cells infected with Adeno-FADD or Adeno-LacZ.
- the effect of introducing the FADD gene in type II collagen-induced arthritis was examined using the degree of arthritis as an index.
- Emulsion was prepared by mixing 0.05 N acetic acid solution (4 mg Zml) of type II collagen derived from articular cartilage and an equal volume of complete Freund's adjuvant.
- the marjon was administered intradermally at the base of the ridge of DBAZ1J mice at 100 Ojt1 (type II collagen: 200; equivalent to zgZ mice). Twenty-one days after the primary sensitization, this emulsion was administered again to the skin at the base of the ridge of mice in a dose of 1001 (secondary sensitization).
- the onset of arthritis was determined when swelling of the joint site with erythema was observed.
- the degree of arthritis was scored according to the following arthritis evaluation criteria.
- Fig. 3 shows the scoring of arthritis in the Adeno-FADD injection group, the Adeno-FADD injection group and the vehicle injection group (hereinafter referred to as the control group).
- the present invention relates to a novel means for treating rheumatism by specifically inducing apoptosis in abnormally proliferating synovial cells of a rheumatic patient.
- a therapeutic agent for rheumatism comprising a FADD (Fas associated death domain protein) gene as an active ingredient.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Marine Sciences & Fisheries (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Cette invention concerne un système qui permet de traiter les rhumatismes et qui induit l'apoptose de manière spécifique parmi les cellules synoviales proliférant de manière anormale chez les patients atteints de rhumatismes. Cette invention concerne également des remèdes contre les rhumatismes qui contiennent un gène FADD en qualité d'ingrédient actif. Ce gène FADD consiste de préférence en un gène capable d'induire l'apoptose, un mode de mort cellulaire programmée, parmi les cellules synoviales de patients atteints de rhumatismes. Le gène FADD peut être intégré à un vecteur, tel qu'un vecteur d'adénovirus.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10/306573 | 1998-10-28 | ||
| JP30657398 | 1998-10-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2000024427A1 true WO2000024427A1 (fr) | 2000-05-04 |
Family
ID=17958694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP1999/005988 WO2000024427A1 (fr) | 1998-10-28 | 1999-10-28 | Remedes contre les rhumatismes contenant un gene fadd en qualite d'ingredient actif |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2000024427A1 (fr) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996031603A2 (fr) * | 1995-04-03 | 1996-10-10 | The Regents Of The University Of Michigan | Procedes et compositions pour reguler le niveau de la proteine 'fadd' |
| WO1998003648A1 (fr) * | 1996-07-19 | 1998-01-29 | Takeda Chemical Industries, Ltd. | Proteine similaire au ligand fas, son procede de production et d'utilisation |
-
1999
- 1999-10-28 WO PCT/JP1999/005988 patent/WO2000024427A1/fr active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996031603A2 (fr) * | 1995-04-03 | 1996-10-10 | The Regents Of The University Of Michigan | Procedes et compositions pour reguler le niveau de la proteine 'fadd' |
| WO1998003648A1 (fr) * | 1996-07-19 | 1998-01-29 | Takeda Chemical Industries, Ltd. | Proteine similaire au ligand fas, son procede de production et d'utilisation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8901081B2 (en) | Uses of GRS proteins or fragments thereof | |
| ES2717839T3 (es) | Extractos de plantas que contienen cannabinoides para el tratamiento del cáncer de próstata | |
| KR20170001756A (ko) | 유착 치료 또는 예방용 폴리펩티드 | |
| CN102462837B (zh) | 抗炎组合物 | |
| WO2021244010A1 (fr) | Utilisation d'une protéine de liaison à facteur de choc thermique 2 pour des atteintes hépatiques d'ischémie-reperfusion et des atteintes hépatiques médicamenteuses | |
| JP6576251B2 (ja) | ＰＴＤ−Ｓｍａｄ７薬物療法 | |
| WO2022156026A1 (fr) | Utilisation de lncrna xr_595534.2 dans la préparation d'un médicament pour le traitement ou la prévention de la douleur chronique | |
| CN108283643A (zh) | 一种噻嗪二酮类化合物在制备预防或治疗类风湿性关节炎的药物中的应用 | |
| IL168639A (en) | A preparation containing streptolysin O for the treatment of connective tissue diseases | |
| JP2022548373A (ja) | ヒトにおける変形性関節症の処置における使用のための有効用量のアデノウイルスに基づく生物学的送達および発現系、ならびにそれを含む組成物 | |
| WO2000024427A1 (fr) | Remedes contre les rhumatismes contenant un gene fadd en qualite d'ingredient actif | |
| WO2004043485A1 (fr) | Composition presentant des proprietes antioxydantes, procede de production d'un polypeptide et methode de traitement | |
| CN114588164B (zh) | 瑞马唑仑在预防围术期低体温和寒战中的应用 | |
| CN110711244B (zh) | 一种神经导向因子Sema在制备治疗骨关节炎搽剂中的应用 | |
| HU230294B1 (hu) | IL-18-inhibitorok alkalmazása központi idegrendszeri sérülések kezelésére vagy megelőzésére | |
| CN116115760A (zh) | Eed抑制剂在制备治疗神经免疫性疾病药物中的应用 | |
| TW202039531A (zh) | 用於治療平滑肌功能不良之組成物及方法 | |
| CN114917342A (zh) | Arhgap44促进剂在抑制阿片类药物诱发的痛觉过敏中的应用 | |
| WO2012129767A1 (fr) | Composition pharmaceutique comprenant un hydrogel d'agarose modifié par des cations et un acide nucléique, son procédé de préparation et son utilisation | |
| TWI737972B (zh) | 心肌再灌流的方法及套组與減緩或減少心肌再灌流損傷的方法 | |
| JP2000198737A (ja) | Ｆａｄｄ遺伝子を活性成分とするリウマチ治療剤 | |
| JP2004536827A (ja) | Ａｂｉｎにより媒介される肝炎防護 | |
| CN113304163B (zh) | 三叶豆紫檀苷在治疗关节炎中的用途 | |
| CN115400137B (zh) | 香蜂草苷在制备治疗骨关节炎药物中的应用 | |
| JP5197887B2 (ja) | イミュノグロブリン結合能を有するペプチド |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA CN KR NO US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase |